Amarin Q3 revenue up 17%, operating loss narrows

Amarin

29/10/2025 11:18

Overview

Amarin Q3 2025 total net revenue rises 17% yr/yr, driven by higher U.S. sales

Operating expenses fell 20% in Q3 2025 due to restructuring efforts

Company's operating loss improves, reflecting restructuring impact

Outlook

Amarin targets sustainable positive free cash flow in 2026

Company expects steady operating margin and cash flow improvements

Result Drivers

PARTNERED MODEL - Transition to partnered commercialization model in Europe affected sales, per CFO Peter Fishman

RESTRUCTURING IMPACT - Significant decrease in operating expenses due to restructuring, leading to improved operating margin

U.S. SALES GROWTH - Higher net selling price and regained exclusive status with a large PBM drove U.S. sales increase

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$49.70 mln
Q3 Operating Expenses
$33.29 mln


Analyst Coverage

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Amarin Corporation PLC is $10.00, about 89.4% below its October 28 closing price of $18.94

Press Release: ID:nGNX2mD21Z

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)